Home›Stocks›KYMR

KYMR — structural market context

Kymera Therapeutics, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Nov 4. Each line shows the earlier value, the later value and their dates.

Price

Change from the Nov 3 close to the Nov 4 close: +7.21%.

Volume

1.99× its 20-session average on Nov 4.

Includes pre- and post-market trading.

Short interest

Short interest 9.2M shares (settlement Oct 15) vs 9.9M (Sep 30).

No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.

Fails-to-deliver

Latest file (settlements Oct 1–Oct 14, published Nov 3): 3 days with fails, largest 4K shares on Oct 13.

Previous file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 1K shares on Sep 22.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

Events · early sample

None recorded in this window.

KYMR events and their magnitude

Latest SEC filing in the event study

8-K 2.02 · Earnings release · filed 2026-10-29 · View on sec.gov ↗

…

How the Event Study works →

KYMR short interest & days to cover

SHARES SHORT
9.2M
% OF FLOAT
13.9%
DAYS TO COVER
10.0
CHANGE VS PRIOR
-7.5%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (21d ago)

How short interest and days to cover are measured →

KYMR fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-10-14 · 22d1$106.68
2026-10-13 · 23d4K$112.08
2026-10-02 · 34d2K$110.12

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

How fails-to-deliver are reported →

KYMR insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 9 sales

InsiderTypeSharesValueFiled
Mainolfi Nello · director, officer: Chief Executive OfficerSale (S)262$30K2026-10-01
Mainolfi Nello · director, officer: Chief Executive OfficerSale (S)5K$552K2026-10-01
Mainolfi Nello · director, officer: Chief Executive OfficerSale (S)8K$870K2026-10-01
Mainolfi Nello · director, officer: Chief Executive OfficerSale (S)8K$950K2026-10-01
Mainolfi Nello · director, officer: Chief Executive OfficerSale (S)4K$393K2026-10-01

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

Form 4 transaction codes explained →

KYMR offering filings (SEC)

3 SEC filings in the last 12 months, none in the last 90 days. The most recent: Prospectus supplement filed under Rule 424(b)(5) 424B5, filed 2026-02-26. View on sec.gov ↗

SEC filings listed by filing date. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price. Some of these filings cover debt securities or resales by existing holders. A filing is made by the issuer and appears under each of its tickers. Source: SEC EDGAR daily index; each filing links to its page on sec.gov.

Offering registration and prospectus filings (S-1, S-3, F-1 and F-3 with their amendments, S-3ASR, F-3ASR, 424B4 and 424B5) on SEC EDGAR in the last 12 months, each counted once.

SEC offering filings explained →

KYMR analyst ratings

FirmActionRatingPublished
OppenheimerholdOutperform2026-10-29
Oppenheimerprice_target—2026-10-29
Brookline CapitalholdBuy2026-10-29
Loop Capital Marketsprice_target—2026-10-29
Raymond JamesholdOutperform2026-10-29

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

What is KYMR's short interest?
As of the FINRA settlement date 2026-10-15, KYMR had 9.2M shares sold short — 13.9% of its float, with 10.0 days to cover at average volume. FINRA publishes this data roughly two weeks after each twice-monthly settlement, so it is inherently delayed. A short-interest figure describes an aggregate position; it does not predict what the stock will do.
Are insiders buying KYMR?
In the last 12 months of SEC Form 4 filings, KYMR recorded 0 insider purchases and 9 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What are the SEC offering filings listed for KYMR?
They are registration statements (Forms S-1, S-3, F-1 and F-3, with their amendments and the S-3ASR and F-3ASR automatic shelf forms) and prospectuses filed under Rule 424(b)(4) or 424(b)(5). In the last 12 months the issuer of KYMR filed 3; the most recent was a prospectus supplement filed under Rule 424(b)(5) on 2026-02-26. A registration statement or prospectus does not by itself show that any shares were sold, how many, or at what price, and some of these filings cover debt securities or resales by existing holders.
What do analysts say about KYMR?
The most recent action: Oppenheimer hold to Outperform on 2026-10-29. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell KYMR?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

Other companies in the same SEC industry: Biological Products, (No Diagnostic Substances)

BIIB · Biogen Inc.CGEM · Cullinan Therapeutics, Inc. CoELOX · Eloxx Pharmaceuticals, Inc. CoREPL · Replimune Group, Inc.RGEN · Repligen CorporationRVMD · Revolution Medicines, Inc.

Industry: SIC code 2836 as recorded on SEC EDGAR.

All tickers starting with K →

KYMR: the full history

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.

Sign up with Google or emailCreate a free account